Guizhou Bailing Group Pharmaceutical Co Ltd

Overview

Guizhou Bailing Group Pharmaceutical Co Ltd (Bailing Group) operates as a pharmaceutical products manufacturer and distributor. The company researches, develops, produces, and sells Chinese medicines in China. It offers products in the areas of cardiovascular and cerebrovascular, abnormal lipid metabolism, cold cough, and gynecological diseases. Bailing Group offers medicines in the form of tablets, capsules, syrups, soft capsules, hard capsules, granules, pills, powders, sprays, decoctions, elixirs, dripping pills, large-volume injections, and small-volume injections. Its products are used for treatment of cardiovascular and cerebrovascular diseases, cough, common cold, and fever. The company has operations within domestic markets. Bailing Group is headquartered in Anshun,China.
Key Stats
Address
Xihang Avenue, Economic And Tchnlgcl Dvlpmnt Zn, Anshun, Guizhou
Headquarters

China

Contact

86 851 33415126

Website
www.gzbl.com
No of Employees

6,074

Industry

Consumer Packaged Goods

Ticker Symbol & Exchange​

002424 [SZSE]

Revenue (2020)

$448 m

8.6% (2020 vs 2019)
Net Income (2020)

$22 m

-46.3% (2020 vs 2019)
Net Profit Margin

5 %

-50.3% (2020 vs 2019)
Market Cap *

$1,359 m

EPS *

$0.1

  *Note: Ratios based on the share price as of 30-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Guizhou Bailing Group Pharmaceutical Co LtdGuizhou Xinbang Pharmaceutical Co Ltd
Key Information
Headquarters China China
Headquarter City Anshun Guiyang
Headquarter State/Province Guizhou Guizhou
No. of Employees 6,074 5,778
Entity Type Public Public

Products & Services

Bailing Group principally engaged in the manufacture and distribution of Chinese patent medicines. The company offers key products in the following categories

Products
  • Products
  • Cardiovascular and Cerebrovascular
  • Abnormal Lipid Metabolism
  • Vitae Eget Libero
  • Vitae Eget Libero
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In March, the company entered into an agreement to sell its 5.23% stake to Anshun…

Locations


Guizhou Bailing Enterprise Group Herentang Pharmaceutical Co., Ltd.
Guizhou Bailing Enterprise Group Zhengxin Pharmaceutical Co., Ltd.
Inner Mongolia Jinling Pharmaceutical Co., Ltd.
Guizhou Bailing Chinese Medicine Diabetes Hospital Co., Ltd.
Guizhou Zhongling Guanghui Medical Pharmaceutical Health Industry Development Co., Ltd.
Tibet Jinling Pharmaceutical Technology Development Co., Ltd.
Bailing Chinese Medicine Diabetes Hospital (Changsha) Co., Ltd.
Yunnan Hongling Biological Technology Co., Ltd.

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target